The role of novel T cell costimulatory pathways in autoimmunity and transplantation

Journal of the American Society of Nephrology

Volumn 13, Issue 2, 2002, Pages 559-575

  Yamada, Akira ^a   Salama, Alan D ^a   Sayegh, Mohamed H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

AUTOIMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION;

EID: 0036156661     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (183)

1. A theory of self-nonself discrimination
2. Signals and signs for lymphocyte responses
3. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
4. The role of the CD28 receptor during T cell responses to antigen
5. The B7 and CD28 receptor families
6. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation
7. New perspectives of CD28-B7-mediated T cell costimulation
8. The role of T-cell costimulatory activation pathways in transplant rejection
9. CTLA-4 is a second receptor for the B cell activation antigen B7
10. CTLA-4 can function as a negative regulator of T cell activation
11. CTLA-4 ligation blocks CD28-dependent T cell activation
12. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regualtory role of CTLA-4
13. Lymphoproliferative disorders with early lethality in mice deficient in CTLA4
14. Induction of peripheral T cell tolerance in vivo required CTLA-4 engagement
15. CTLA-4 regulates induction of anergy in vivo
16. Acquired thymic tolerance: Role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model
17. Is CTLA-4 a master switch for peripheral T cell tolerance?
18. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo
19. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
20. Transplantation tolerance induced by CTLA4-Ig
21. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism
22. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
23. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD 28:B 7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis
24. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection
25. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen
26. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection
27. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis
28. Chronic blockade of CD28-BT-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts
29. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allografts
30. The role of CD80, CD86, and CTLA 4 in alloimmune responses and the induction of long-term allograft survival
31. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2
32. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts
33. Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival
34. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28
35. CD28 independent costimulation of T cells in alloimmune responses
36. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice
37. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection
38. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis
39. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/Ipr lupus
40. B7 costimulation in the development of lupus: Autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B 7.2 blocking antibodies
41. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
42. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model
43. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis
44. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
45. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis
46. CD28-deficient mice are highly resistant to collagen-induced arthritis
47. B7.2 has opposing roles during the activation versus effector stages of experimental autoimmune thyroiditis
48. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis
49. CD28-independent induction of experimental autoimmune encephalomyelitis
50. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
51. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte -associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
52. Finally, CTLA4Ig graduates to the clinic
53. CD40 and its ligand in host defense
54. Defects of T-cell effector function and post-thymic maturation in X- linked hyper-IgM syndrome
55. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction
56. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal
57. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp 39 pathway
58. Costimulatory function and expression of CD40 ligand. CD80 and CD86 in vascularized murine cardiac allograft rejection
59. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
60. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes
61. CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade
62. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
63. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis
64. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance
65. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
66. Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning
67. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
68. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
69. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation
70. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
71. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154
72. CD154-CD40 pathway in transplantation
73. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
74. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction
75. Blocking both signal I and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
76. T cell death and transplantation tolerance
77. CTLA-4 up-regulation plays a role in tolerance mediated by CD45
78. New insights into the interaction between costimulation blockade and conventional immunosuppression in vivo
79. A novel CD154 monoclonal antibody in acute and chronic rat vascularised cardiac allograft rejection
80. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
81. Anti-CD154 (CD40L) prevents recurrence of diabetes in islet isografts in the DR-BB rat
82. Prolonged islet graft survival in NOD mice by blockade of the CD40- CD154 pathway of T-cell costimulation
83. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice
84. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system
85. T cell co-stimulatory molecules other than CD28
86. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
87. T-cell co-stimulation through B7RP-1 and ICOS
88. LICOS, a primordial costimulatory ligand?
89. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7- 1
90. Characterization of human inducible costimulator ligand expression and function
91. Cutting edge: Identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor
92. B7h, a novel costimulatory homolog of B7.1 and B7. 2, is induced by TNFalpha
93. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand
94. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses
95. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
96. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells
97. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection
98. B7RP-1 a novel renal tubular epithelial antigen with costimulatory function
99. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection
100. ICOS is critical for CD40-mediated antibody class switching
101. ICOS co-stimulatory receptor is essential for T-cell activation and function
102. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE
103. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
104. PD-L2 is a second ligand for PD-I and inhibits T cell activation
105. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
106. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice
107. TNF-alpha receptor 1 (p55) on islets is necessary for the expression of LIGHT on diabetogenic T cells
108. Inducible T cell antigen 4-1BB. Analysis of expression and function
109. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: A member of an emerging family of cytokines with homology to tumor necrosis factor
110. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
111. Signals through 4-1BB are costimulatory to previously activated T cells and inhibit activation-induced cell death
112. Costimulation of CD28-Tlymphocytes by 4-1BB ligand
113. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells
114. CD137-induced apoptosis is independent of CD95
115. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell response
116. Cutting Edge: 4-1BB is a bona fide CD8 T cell survival signal
117. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
118. Costimulation of antigen-specific CD4 T cells by 4-1BB ligand
119. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy
120. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses
121. Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation
122. 4-1Bb ligand induces cell division, sustains survival, and enhances effector function of cd4 and cd8 t cells with similar efficacy
123. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28+ T cells
124. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses
125. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine
126. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors
127. Potential role of 4-1BB in T cell activation
128. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP
129. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
130. Structure and expression of murine CD30 and its role in cytokine production
131. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines
132. BER-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope
133. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals
134. CD30 expression does not discriminate between human Th1- and Th2-type T cells
135. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines
136. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF
137. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice
138. CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity
139. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors
140. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines
141. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis
142. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells
143. The role of CD30 in skin and heart allograft rejection in the mouse
144. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-a molecule related to nerve growth factor receptor
145. Cloning of mouse Ox40: A T cell activation marker that may mediate T-B cell interactions
146. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen
147. Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor
148. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor
149. Antibodies to OX-40 (CD134) can identify and eliminate autoreactive T cells: Implications for human autoimmune disease
150. Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues
151. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells
152. Expression and function of OX40 ligand on human dendritic cells
153. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells
154. Identification of rat OX40 ligand by molecular cloning
155. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses
156. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers
157. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion
158. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions
159. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection
160. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand
161. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40)
162. Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease
163. CD4 T cell traffic control: In vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles
164. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40
165. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, B1r-1
166. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance
167. OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis
168. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis
169. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein
170. Amelioration of experimental autoimmune encephalomyelitis with anti- OX40 ligand monoclonal antibody: A critical role for OX40 ligand in migration, but not development, of pathogenic T cells
171. Critical involvement of ox40 ligand signals in the t cell priming events during experimental autoimmune encephalomyelitis
172. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells
173. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2
174. CD27-mediated activation of murine NK cells
175. Characterization of murine CD70, the ligand of the TNF receptor family member CD27
176. Characterization of murine CD70 by molecular cloning and mAb
177. CD27 is required for generation and long-term maintenance of T cell immunity
178. Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T -cell response to follicular lymphoma cells
179. CD27/CD70 interactions regulate T dependent B cell differentiation
180. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis
181. Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response
182. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status
183. Challenges to achieving clinical transplantation tolerance